Skip to main content

Table 2 Clinical parameters and SREBPs expression in low-risk complexity, high-risk complexity and non-CAD control participants

From: Down-regulated of SREBP-1 in circulating leukocyte is a risk factor for atherosclerosis: a case control study

Characteristic

CAD patients

Non-CAD Controls

n = 178

P value

GROUP A1

n = 77

Group B 2

n = 141

P 3

P 4

Demographics

 Age (years)

58.33 ± 9.28

59.32 ± 9.35

58.98 ± 9.32

0.617

0.114

 Male

45

96

141

  

Clinical parameters

 TC (mmol/L)

3.94 ± 1.01

3.64 ± 1.06

4.81 ± 0.94

< 0.001

< 0.001

 TG (mmol/L)

1.32(0.88, 2.03)

1.15(0.69, 2.06)

1.26(0.82, 1.48)

0.004

0.335

 HDL-C (mmol/L)

1.08 ± 0.26

0.97 ± 0.25

1.41 ± 0.33

< 0.001

< 0.001

 LDL-C (mmol/L)

1.97 ± 0.68

1.87 ± 0.71

2.27 ± 0.59

< 0.001

< 0.001

 Apo-A1 (g/L)

1.57 ± 0.26

1.43 ± 0.29

1.62 ± 0.21

0.157

< 0.001

 Apo-B (g/L)

0.82 ± 0.22

0.82 ± 0.25

0.91 ± 0.21

0.002

< 0.001

 LP(a) (mg/L)

102.8 ± 92.61

123.70 ± 110.20

78.20 ± 84.93

0.048

< 0.001

 AST (IU/L)

23.0(16.5, 29.0)

23.00(18.00, 37.00)

25.14(20.00, 29.17)

0.314

0.488

 CK-MB (IU/L)

16.66 ± 10.10

15.38 ± 10.27

8.43 ± 6.90

< 0.001

< 0.001

 LDH (IU/L)

190.13 ± 47.62

195.52 ± 74.70

187.43 ± 42.60

0.655

0.783

 HBDH (IU/L)

124.81 ± 37.79

130.14 ± 58.08

119.69 ± 30.05

0.250

0.050

 hs-CRP (mg/L)

6.13(4.51, 8.27)

8.05(4.81, 14.90)

5.26(2.17, 5.71)

< 0.001

< 0.001

 HCY (μmol/L)

9.90(7.50,12.45)

11.75(8.65, 13.68)

11.30(8.90,12.50)

0.190

0.007

 CysC (mg/L)

0.59 ± 0.21

0.61 ± 0.22

0.59 ± 0.14

0.882

0.323

 GSP (mmol/L)

2.70(2.43, 2.94)

2.57(2.37, 2.86)

2.61(2.46, 2.74)

0.089

0.856

SREBP-1 (fold change)

0.85 ± 1.15

0.56 ± 1.12

1.00 ± 1.17

0.357

0.001

SREBP-2 (fold change)

1.12 ± 1.29

0.83 ± 1.39

1.00 ± 0.89

0.450

0.206

  1. 1 Group A, SYNTAX score of < 23; 2 Group B, SYNTAX score of ≥23; 3 Group A compare with non-CAD controls; 4 Group B compared with non-CAD controls
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X